Han.biomedical Inc.

NT$24.45As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6999Healthcare

Country Taiwan

PE (Fwd) 22.68

TSR 2Y CAGR (15.42%)

Div yield —

ROE 8.86%

Biotechnology

Beta (5Y) —

PE TTM 25.06

TSR TTM (26.36%)

Mkt cap NT$565.2M

ROIC 15.58%

SE Grade™

Value

Quality

Moat

1Y Price

Reference

NT$25

3.35%

20.74%

Price below Reference Value

TTM

FYE 31 Dec TWD

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

126.2

RevenueNT$M

—

93.98

96.84

115.3

126.2

132.3

10.33%

—

9.46

Revenue growth%

—

3.04

19.06

9.46

4.83

9.46

—

78.13

Gross margin%

—

64.48

72.76

73.77

78.13

78.65

73.26

—

19.49

Operating margin%

—

25.31

26.27

23.97

19.49

19.55

24.64

—

17.88

Net margin%

—

19.94

22.24

21.06

17.88

18.02

20.50

—

25.06

P/E ratio (avg)x

—

31.64

35.76

23.71

33.70

—

20.00

EV/EBITx

—

23.44

29.83

19.58

26.64

—

(2.47)

FCF yield (avg)%

—

3.96

(1.73)

(2.49)

1.11

—

(11.08)

FCF margin%

—

24.50

31.81

26.39

(11.08)

(10.63)

25.44

—

(0.620)

FCF / Net incomex

—

1.228

1.430

1.253

(0.620)

(0.590)

1.241

—

15.58

ROIC%

—

37.63

25.89

21.09

15.58

12.56

23.49

—

8.86

Return on equity%

—

10.08

10.95

10.64

8.86

8.77

10.36

—

7.45

Return on assets%

—

8.83

9.39

8.92

7.45

7.29

8.88

—

0.98

EPSNT$

—

0.86

0.98

1.07

0.98

1.03

4.38%

—

(8.69)

EPS growth%

—

13.66

9.57

(8.69)

5.68

9.57

—

11.24

Bookvalue per shNT$

—

8.51

9.39

10.96

11.24

12.28

9.73%

—

(0.60)

FCF per shareNT$

—

1.05

1.39

1.34

(0.60)

(0.61)

12.72%

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

23.12

Shares (diluted)M

—

21.84

22.09

22.73

23.13

◌23.13

1.92%

—

(1.78)

Buyback yield%

—

(1.13)

(2.87)

(1.78)

◌—

(1.78)

—

0.071

D/E ratiox

—

0.053

0.026

—

0.071

0.065

0.039

—

492.0

Enterprise valueNT$M

—

648.0

733.7

506.4

13.22%

—

LT debtNT$M

—

Peers (US$17.11M)

Cap (US$)

Genomics BioSci…

34.79M

—

FullHope Biomedical…

31.34M

—

SMOBiO Technology, Inc

19.68M

—

CCME Global Limited

18.76M

—

Capital

TTM

10Y

Leveragex

(2.207)

(2.640)

EBIT/Intx

58.98

152.6

Own earn%

—

Sh yield%

(1.78)

Owners

Insiders/Inst%

43.76

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

4/4

Revenue growth years

3/3

EPS growth years

2/3

Dividend streakyrs

Op margin range%

19–26

$1 testx

—

Incr. ROIC%

Han.biomedical Inc. develops structured biomaterials for tissue regeneration in Taiwan. It offers BarriGel adhesion prevention gel; HANBIO patient lubricant; HANCARE collagen matrix; HANBIO gauze; and LEOFOR hyaluronic acid solution. The company is based in New Taipei City, Taiwan.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

NT$126.2M

10.33%

1.00×

Cost of revenue

NT$27.60M

(6.15%)

0.62×

Operating expenses

NT$74.02M

26.21%

1.50×

Asset mix

Trend

Other

69.75%

Cash and investments

30.25%

Reinvestment returns

No breakdown available